



November 13, 2024

The Manager (Listing)
BSE Limited
Phiroze Jeejeebhoy Towers
Dalal Street, Fort
Mumbai 400001

Dear Sir/Madam,

Scrip code: 543916

Sub.: Outcome of the Board Meeting pursuant to Regulation 30 and 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 held on Wednesday, November 13, 2024.

Dear Sir/Madam,

With reference to the captioned subject and in compliance with the regulation 30 and 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, this is to inform you that the Board of Directors of the Company at its meeting held today i.e. Wednesday, November 13, 2024 inter-alia have considered and approved the un-audited Financial Results of the Company for the half year ended on September 30, 2024.

A copy of the un-audited Financial Results adopted and approved by the Board of Directors for the half year ended on September 30, 2024 along with limited review report of the Auditors thereon is attached herewith.

The Meeting was commenced at 04.30 p.m. and concluded at 05.00 p.m.

Please take the same on your records and suitably disseminated at all concerned.

Thanking you,

Yours faithfully,
For Hemant Surgical Industries Limited

Hanskumar Shamji Shah
Managing Director
DIN: 00215972
Email id: hanskumar@hemantsurgical.com

Encl.: As above

Independent Auditor's Review Report on the Unaudited Half Yearly Financial Results of Hemant Surgical Industries Limited pursuant to the regulation 33 of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015 as amended

To,
The Board of Directors
Hemant Surgical Industries Limited

1. We have reviewed the accompanying Statement of Unaudited Standalone Financial Results of **Hemant Surgical Industries Limited** ("the Company"), for the half year ended September 30, 2024 ("the Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended (hereinafter referred to as "Listing regulations").
2. The Company's management is responsible for the preparation of the Statement in accordance with the recognition and measurement principles laid down in Accounting Standard 25 "Interim Financial Reporting" prescribed under section 133 of the companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. The Statement has been approved by the Company's Board of Directors. and in compliance with Regulation 33 of Listing Regulations. Our responsibility is to issue a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with the Standards on Auditing specified under section 143(10) of the Act, and consequently, does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement prepared in accordance with applicable Accounting Standards (AS) and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For A D V & Associates
Chartered Accountants
FRN: 128045W



Pratik Kabra
Partner

M. No.: 611401

Date: 13th November, 2024

UDIN: 24611401BKCLMR4309

Place: Mumbai



HEMANT SURGICAL INDUSTRIES LIMITED

**ADD : 502,5TH FLOOR, ECSTASY BUSINESS PARK, J.S.D. ROAD, MULUND (W) MUMBAI,
400080**

CIN : U33110MH1989PLC051133

STATEMENT OF ASSETS AND LIABILITIES AS ON SEPTEMBER 30,2024

(Rs in Lakhs)

Particulars	For the period upto 30th September 2024 (Unaudited)	As at March 31, 2024 (Audited)
I Equity & Liabilities		
1.Shareholders funds:		
a.Share Capital	1,044.00	1,044.00
b.Reserves and Surplus	4,760.06	4,441.83
2.Share Application Money pending Allotment:		
3.Non-Current liabilities:		
a.Long-Term Borrowings	952.26	354.22
b.Deferred Tax Liabilities	23.16	6.29
b.Long Term Provisions	48.53	38.20
4.Current Liabilities:		
a.Short Term Borrowings		
b.Trade Payables	492.97	321.08
i. Micro enterprises and small enterprises	202.80	186.42
ii. Other than micro enterprises and small enterprises.	2,482.06	2,274.21
c.Other Current Liabilities	1,287.44	706.91
d.Short Term Provisions	301.02	290.56
Total	11,594.30	9,663.72
II Assets		
1.Non-Current Assets:		
a. Property, Plant & Equipment and Intangible Assets	3313.15	1,766.20
b. Capital Work in progress	13.40	-
c.Non-Current Investments	0.65	492.82
d.Long Term Loans & Advances	481.69	475.08
e. Other Non Current Assets	93.14	
2.Current Assets:		
a.Current Investments		
b.Inventories		
c.Trade Receivables	3,082.52	2,105.04
d.Cash and Cash Equivalents	1,845.74	2,173.66
e.Short Term Loans and Advances	782.36	1,317.06
f.Other Current Assets	1,550.82	1,039.40
Total	430.81	294.46
	11,594.30	9,663.72

For and on behalf of the Board of Directors of
HEMANT SURGICAL INDUSTRIES LIMITED

Hans Kumar

Hans Kumar Shamji Shah
Managing Director
DIN - 00215972
Place : Mumbai
Date: 13th November, 2024



HEMANT SURGICAL INDUSTRIES LIMITED

ADD : 502,5TH FLOOR, ECSTASY BUSINESS PARK, J.S.D. ROAD, MULUND (W) MUMBAI, 400080

CIN : U33110MH1989PLC051133

STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE PERIOD ENDED ON 30 SEPTEMBER,2024

(Rs. In lakhs except EPS)

Particulars	Half Year Ended			Year Ended
	30/09/2024	31/03/2024	30/09/2023	31/03/2024
	(Unaudited)	(Audited)	(Unaudited)	(Audited)
I. Revenue from Operations	4,887.06	5,809.60	4,751.15	10,560.75
II. Other Incomes	240.83	167.10	263.75	430.85
III. Total Revenue (a)	5,127.89	5,976.70	5,014.90	10,991.60
IV. Expenses				
1. Cost of Raw Materials Consumed	4,169.19	3,876.12	4,140.12	8,016.24
2. Change in Inventories	(729.85)	244.61	(509.72)	(265.11)
3. Employee Benefits Expenses	426.00	405.79	353.76	759.55
4. Finance Costs	77.02	45.72	51.43	97.15
5. Depreciation	68.60	52.02	50.61	102.63
6. Other Expenses	669.13	547.82	455.19	1,003.01
V. Total Expenses (b)	4,680.09	5,172.08	4,541.39	9,713.47
V. Profit before Exceptional and Extraordinary Items and Tax	447.80	804.62	473.51	1,278.13
VI. Exceptional Items		-	-	-
VII. Profit Before Extraordinary items and Tax	447.80	804.62	473.51	1,278.13
VIII. Extraordinary Items		-	-	-
IX. Profit before tax	447.80	804.62	473.51	1,278.13
X. Tax Expense				
a. Current Tax	112.70	202.51	119.17	321.68
b. Earlier Year Tax		-	-	-
c. Deferred Tax Expenses	(16.87)	14.40	(37.94)	(23.54)
XI. Profit for the period from Continuing Operations	318.23	587.71	392.27	979.99
XII. Profit from Discontinuing Operations		-	-	-
XIII. Tax Expense of Discontinuing Operations		-	-	-
XIV. Profit from Discontinuing Operations after Tax		-	-	-
XV. Profit for the period	318.23	587.71	392.27	979.99
XVI. Earning per Share (Equated)				
(a) Basic EPS	5.63	5.70	4.15	9.85
(b) Diluted EPS	5.63	5.70	4.15	9.85

For and on behalf of the Board of Directors of
HEMANT SURGICAL INDUSTRIES LIMITED

Hans Kumar Shamji Shah

Hans Kumar Shamji Shah

Managing Director

DIN - 00215972

Place : Mumbai

Date: 13th November, 2024




HEMANT SURGICAL INDUSTRIES LIMITED
ADD : 502,5TH FLOOR, ECSTASY BUSINESS PARK, J.S.D. ROAD, MULUND (W) MUMBAI, 400080
CIN : U33110MH1989PLC051133

STATEMENT OF CASH FLOW FOR THE PERIOD ENDED ON 30 September 2024

(Rs. In lakhs)

Particulars	For the period upto 30th September 2024 (Unaudited)	For the period ended 31st March, 2024 (Audited)
A CASH FLOW FROM OPERATING ACTIVITIES		
Net Profit before tax as per Profit And Loss A/c	447.80	1,278.13
Adjustments for:		
Depreciation & Amortisation Expense	68.60	102.63
Prior Period Depreciation Adjustment		-
Interest Income	(26.27)	(112.09)
Profit on Sale of Fixed Assets	(19.76)	(1.42)
Finance Cost	77.02	94.50
	547.39	1,361.75
Operating Profit Before Working Capital Changes		
Adjusted for (Increase)/ Decrease in:		
Long term provision	10.32	6.58
Short term Borrowings	171.89	(84.95)
Trade Payables	224.23	41.88
Other Current Liabilities	580.53	90.84
Short term provision	10.49	(34.87)
Inventories	(977.48)	(624.37)
Trade Receivables	327.93	(453.86)
Loans and Advances	(518.03)	(566.60)
Other current assets	(136.36)	(170.52)
Cash Generated From Operations	240.91	(434.12)
Appropriation of Profit		
Net Income Tax paid/ refunded	112.75	(321.68)
Net Cash Flow from/(used in) Operating Activities: (A)	128.17	(755.80)
B Cash Flow From Investing Activities:		
Net (Purchases)/Sales of Fixed Assets (including capital work in progress)	(1,723.78)	(552.19)
Sales of Fixed Assets (including capital work in progress)	114.58	
Interest Income	26.27	112.09
Net Increase/(Decrease) in Non Current Investment	492.17	(456.67)
Net Increase/(Decrease) in Other Non Current Assets	(93.14)	
Net Cash Flow from/(used in) Investing Activities: (B)	(1,183.90)	(896.77)
Cash Flow from Financing Activities:		
Net Increase/(Decrease) in Long Term Borrowings	598.05	48.32
Proceeds from issue of share		2,170.16
Interest on borrowings	(77.02)	(94.50)
Net Cash Flow from/(used in) Financing Activities: (C)	521.03	2,123.98
C Net Increase/(Decrease) in Cash & Cash Equivalents (A+B+C)	(534.70)	471.41
Cash & Cash Equivalents As At Beginning of the Year	1317.06	845.65
Cash & Cash Equivalents As At End of the Year	782.36	1,317.06

For and on behalf of the Board of Directors of
HEMANT SURGICAL INDUSTRIES LIMITED


Hanskumar Shamji Shah
 Managing Director
 DIN - 00215972
 Place: Mumbai
 Date: 13th November, 2024



HEMANT SURGICAL INDUSTRIES LIMITED

ADD : 502,5TH FLOOR, ECSTASY BUSINESS PARK, J.S.D. ROAD, MULUND (W) MUMBAI, 400080

CIN : U33110MH1989PLC051133

NOTES TO FINANCIAL RESULTS FOR THE PERIOD ENDED ON 30th September, 2024

1	The above unaudited financial results of Hemant Surgical Industries Limited ("the Company") for the half year ended September 30, 2024 have been reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on November 13, 2024.
2	The above unaudited financial results of the Hemant Surgical Industries Limited for the half year ended September 30, 2024, are prepared in accordance with the recognition and measurement principles laid down in Accounting Standard (AS) 25 - Interim Financial Reporting, prescribed under section 133 of the Companies Act, 2013 and other recognised accounting principles generally accepted in India.
3	As per MCA Notification dated 16th February, 2015 Companies whose shares are listed on SME exchange as referred to in Chapter XB of SEBI (Issue of Capital and Disclosure Requirements) Regulation, 2009, are exempted from the compulsory requirement of adoption of IND-AS.
4	In terms of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, the unaudited financial results for the half year ended September 30, 2024 has been reviewed by Statutory Auditors of the Company.
5	On 25th September, 2024, the company experienced a fire incident at its manufacturing unit located in Sonale, which resulted in significant damage to certain assets and inventory. The company's inventory was partially damaged in the fire. However, the inventory is covered under an insurance policy, and the company is in Procedure for filing the claim with the insurer. Based on preliminary assessments, the company expects to recover the value of the damaged inventory, subject to the final settlement of the claim. Certain assets (Solar Equipment and Other Assets) were also destroyed or damaged in the fire. These assets are not covered by insurance. As a result, the company has recognized an impairment loss related to the destruction of the non-insured assets, and this loss has been accounted for as [impairment expense/provision] in the financial statements. The estimated loss in Property Plant and Equipment 86.53 Lakhs.
6	The Company is operating in a Single Segment. Hence, the above financial results are based on single segment only.
7	Earning Per share: Earning Per share is calculated on the weighted average of the share capital received by the company. Half yearly EPS is not annualised.
8	Figures of half year ended on March 31, 2024 represent the difference between the audited figures in respect of full financial years and the published unaudited figures of six months ended on September 30, 2023.
9	The figures of the previous period have been re-grouped or rearranged, wherever considered necessary.
10	The Proceeds of IPO have been utilised till September 30, 2024 as per the below mentioned table:

(Amount in Lakhs)

Object of the Issue	Amount Allocated for the Object	Amount Utilised	Balance Available in Bank	Balance Available as Fixed Deposits
Public Issue Expenses	313.88	313.88	-	-
To meet Working Capital Requirement	1,000.00	1,000.00	-	-
Funding Capital Expenditure towards installation of additional plant and	751.26	494.58	-	256.68
General Corporate Purpose	418.86	418.86	-	-
Total	2,484.00	2,227.32	-	256.68

For and on behalf of the Board of Directors of
HEMANT SURGICAL INDUSTRIES LIMITED

Hans Kumar

Hans Kumar Shamji Shah
Managing Director
DIN - 00215972
Place: Mumbai
Date: 13th November, 2024

